30
Participants
Start Date
May 15, 2023
Primary Completion Date
September 15, 2026
Study Completion Date
September 15, 2026
EVER001
A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
EVER001
A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
RECRUITING
The Second Xiangya Hospital Of Central South University, Changsha
RECRUITING
The First Affiliated Hospital of PLA Army Medical University, Chongqing
RECRUITING
The Third Affiliated Hospital,Sun Yat Sen University, Guangzhou
RECRUITING
Peking University Shenzhen Hospital, Shenzhen
RECRUITING
The Second Affiliated Hospital of Harbin Medical University, Harbin
RECRUITING
Xiangya Third Hospital, Central South University, Changsha
RECRUITING
The First Affiliated Hospital of Baotou Medical College, Baotou
RECRUITING
Zhongda Hospital Southeast University, Nanjing
RECRUITING
The Second Affiliated Hospital of Soochow University, Suzhou
RECRUITING
The Second Affiliated Hospital of Nanchang University, Nanchang
RECRUITING
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
RECRUITING
The First Affiliated Hospital of Medical college of Xi'an Jiaotong University, Xian
RECRUITING
Sichuan Province People's Hospital, Chengdu
RECRUITING
Second Hospital of Shanxi Medical University, Shanxi
RECRUITING
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
RECRUITING
Zhejiang Provincial People's Hospital, Hangzhou
RECRUITING
The first affliated hospital of NingBo university, Ningbo
RECRUITING
Taizhou Hospital of Zhejiang Province, Taizhou
RECRUITING
Peking University First Hospital, Beijing
Everest Medicines (China) Co.,Ltd.
INDUSTRY